Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Aug 9, 2024
Product Development
From rare to ultrarare to prevalent: Jim Wilson on gene therapy’s future
BioCentury’s Q&A with Jim Wilson, AAV pioneer and founder of GemmaBio and Franklin Biolabs
BioCentury | Apr 30, 2024
Regulation
Quantifying impact of accelerated approval on life extension
Study attributes over 260,000 additional life years in 2006-22 to accelerated approval
BioCentury | Jan 31, 2024
Distillery Therapeutics
Optimized B7-H3 ADC with PBD payload for solid tumors
BioCentury | Jan 16, 2024
Data Byte
2023 ties record for FDA approvals with companion diagnostics
Last year matched 2018’s record for FDA product approvals accompanied by pharmacogenomic tests
BioCentury | Jul 25, 2023
Politics, Policy & Law
IRA creating ‘dilemmas’ for drug companies, Genentech CEO says
Alexander Hardy describes tensions between maximizing returns on investments and speeding drugs to patients
BioCentury | Apr 29, 2023
Regulation
Lynparza panel vote advances FDA’s precision oncology agenda
ODAC votes for a biomarker-restricted label for Lynparza in prostate cancer
BioCentury | Apr 7, 2023
Politics, Policy & Law
The IRA is coming into focus
Adverse consequences, opportunities — and possible legal challenges — becoming clearer
BioCentury | Dec 21, 2022
Deals
Jazz in tune with Zymeworks’ biliary cancer data, opts in for $325M
Deepening commitment to oncology, Jazz elects to maintain license for dual HER2 bispecific; Phase IIb results this week could suffice for targeted approval
BioCentury | Nov 21, 2022
Data Byte
Signs Western companies are turning to China for cancer innovation
Over half of the cancer therapies Chinese companies out-licensed in 2021-22 employ new modalities or unapproved targets
Items per page:
1 - 10 of 1277